Literature DB >> 12538676

The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors.

Se-Ho Park1, Tim Kyin, Albert Bendelac, Claude Carnaud.   

Abstract

IL-12 is a potent cytokine that impairs the growth of several tumors in vivo in natural as well as in therapeutic conditions. Although IL-12 can enhance a number of immunological antitumor mechanisms, including those mediated by NK cells and CTL, recent reports have suggested that the mouse CD1d-restricted V alpha 14-J alpha 18 NKT cell was the essential cell type recruited in most, if not all tumor rejection models, including the B16 melanoma. In this study, we have examined and compared the role of NKT cells, T cells, NK cells, and other non-T non-B cells in the rejection of B16 melanoma cells after exogenous administration of IL-12. Surprisingly, our results failed to confirm a necessary role for NKT cells in this model. Instead, we found that NK cells mediated the rejection of liver metastases, whereas other gamma c-dependent non-T non-B cells, possibly lymphoid dendritic cells, were required for rejection of skin tumors. These findings challenge the view that NKT cells are systematically required for IL-12-mediated rejection of tumors, and instead reveal that a variety of effector pathways can be recruited depending on the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538676     DOI: 10.4049/jimmunol.170.3.1197

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences.

Authors:  Aleksandar K Stanic; Jang-June Park; Sebastian Joyce
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

2.  IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

Authors:  Maya Eisenring; Johannes vom Berg; Glen Kristiansen; Elisabeth Saller; Burkhard Becher
Journal:  Nat Immunol       Date:  2010-10-10       Impact factor: 25.606

Review 3.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 4.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

5.  Rapid development of a gamma interferon-secreting glycolipid/CD1d-specific Valpha14+ NK1.1- T-cell subset after bacterial infection.

Authors:  Masashi Emoto; Izumi Yoshizawa; Yoshiko Emoto; Mamiko Miamoto; Robert Hurwitz; Stefan H E Kaufmann
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 6.  Roles of cytotoxic and helper innate lymphoid cells in cancer.

Authors:  Camille Guillerey
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 7.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  Gene Therapy against Murine Melanoma B16F10-Nex2 Using IL-13Ralpha2-Fc Chimera and Interleukin 12 in Association with a Cyclopalladated Drug.

Authors:  Flavia Hebeler-Barbosa; Elaine G Rodrigues; Rosana Puccia; Antonio Cf Caires; Luiz R Travassos
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

9.  Isolation of murine hepatic lymphocytes using mechanical dissection for phenotypic and functional analysis of NK1.1+ cells.

Authors:  Zhong-Jun Dong; Hai-Ming Wei; Rui Sun; Zhi-Gang Tian; Bin Gao
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

10.  Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3.

Authors:  Bianca R Dias; Elaine G Rodrigues; Leonardo Nimrichter; Ernesto S Nakayasu; Igor C Almeida; Luiz R Travassos
Journal:  Mol Cancer       Date:  2009-12-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.